Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center

dc.contributor.authorSirven, Milana Bergamino
dc.contributor.authorFernández Ortega, Adela
dc.contributor.authorStradella, Agostina
dc.contributor.authorMorilla, Idoia
dc.contributor.authorFalo Zamora, Catalina
dc.contributor.authorVázquez, Silvia
dc.contributor.authorCastany, Roser
dc.contributor.authorVillanueva, Rafael
dc.contributor.authorRecalde, Sabela
dc.contributor.authorNavarro Pérez, Valentí
dc.contributor.authorGil Gil, Miguel
dc.contributor.authorPernas, Sònia
dc.date.accessioned2020-07-08T07:21:35Z
dc.date.available2020-07-08T07:21:35Z
dc.date.issued2019-11-21
dc.date.updated2020-07-06T08:27:15Z
dc.description.abstractBackground Eribulin improves survival in pre-treated HER2-negative advanced breast cancer (ABC). However, limited data exist on co-morbidities and central nervous system (CNS) efficacy. The purpose of this study was to review eribulin's efficacy and safety in everyday clinical practice with special focus on age, body mass index (BMI) and central nervous system (CNS) activity. Methods An observational study was conducted in a series of HER2-negative ABC patients treated from January'14-December'17 outside a clinical trial. Objective Response Rate (ORR), Progression Free Survival (PFS), Overall Survival (OS), and association of clinical and pathological variables with outcome were evaluated. Results Ninety-five women were treated with at least one cycle of eribulin. Median age was 57 (33-83), and 18% were obese. Median number of prior chemotherapies for ABC was 3 (2-5) and 76% of patients had visceral metastases, including 21% with CNS involvement. Most tumors were estrogen receptor-positive (79%). ORR and stable disease (SD) at 6 months were 26.2 and 37.5%, respectively. Remarkably, relevant CNS efficacy was observed with eribulin: 20% of patients obtained partial response and 25% SD. Treatment was generally well tolerated and manageable, with 29% grade 3 and 10.9% grade 4 toxicities. Median PFS and OS were 4.1 months (CI95% 3.2-4.9) and 11.1 months (CI95% 9.5-14.7), respectively. Triple-negative disease, > 2organs involved and being younger than 70 years old were independent prognosis factors for worse OS in multivariate analysis. Most patients (75%) progressed in pre-existing metastases sites. Conclusion In everyday clinical practice, eribulin's efficacy seems similar to pivotal trials. CNS-efficacy was observed. TNBC, > 2 organs involved and being younger than 70 years old were independent prognosis factors for worse OS. Remarkably, less incidence of grade 4-toxicity compared to previous studies was found.
dc.format.extent7 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid31753013
dc.identifier.urihttps://hdl.handle.net/2445/168080
dc.language.isoeng
dc.publisherBiomed Central
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s40360-019-0367-x
dc.relation.ispartofBMC Pharmacology & Toxicology, 2019-11-21, vol. 20, num. 68
dc.relation.urihttps://doi.org/10.1186/s40360-019-0367-x
dc.rightscc by (c) Sirven, Milana Bergamino et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationCàncer de mama
dc.subject.classificationTerapèutica
dc.subject.otherBreast cancer
dc.subject.otherTherapeutics
dc.titleReal-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
SirvenMB.pdf
Mida:
811.96 KB
Format:
Adobe Portable Document Format